Pharmacogenomics and -genetics in colorectal cancer

Advanced Drug Delivery Reviews

Volumn 61, Issue 5, 2009, Pages 375-380

  Pohl, Alexandra ^a   Lurje, Georg ^a   Manegold, Philipp C ^a   Lenz, Heinz Josef ^a  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

Predictive markers; Prognostic markers; Response prediction

Indexed keywords

BENEFICIAL EFFECTS; COLORECTAL CANCERS; CYTOTOXIC; MOLECULAR MARKERS; OVERALL SURVIVALS; PATIENT SPECIFICS; PHARMACOGENOMICS; PREDICTIVE MARKERS; PROGNOSTIC MARKERS; RECENT PROGRESS; RESPONSE PREDICTION; THERAPEUTIC EFFICACIES;

TOXICITY;

PATIENT TREATMENT;

BEVACIZUMAB; CETUXIMAB; FLUOROURACIL; FOLINIC ACID; GLUCURONOSYLTRANSFERASE 1A1; IRINOTECAN; LEVAMISOLE; MOLECULAR MARKER; OXALIPLATIN; PANITUMUMAB; PHARMACOLOGICAL BIOMARKER;

BONE MARROW SUPPRESSION; CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; COLORECTAL CANCER; DRUG CYTOTOXICITY; DRUG MONITORING; DRUG RESEARCH; DRUG TARGETING; GASTROINTESTINAL TOXICITY; HUMAN; MICROSATELLITE INSTABILITY; NEUTROPENIA; NONHUMAN; PERIPHERAL NEUROPATHY; PHARMACOGENETICS; PHARMACOGENOMICS; PRIORITY JOURNAL; PROGNOSIS; REVIEW; SKIN MANIFESTATION; TREATMENT OUTCOME; TREATMENT RESPONSE;

ANTINEOPLASTIC AGENTS; CHEMOTHERAPY, ADJUVANT; COLORECTAL NEOPLASMS; HUMANS; NEOPLASM METASTASIS; PHARMACOGENETICS; PROGNOSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 67349262467     PISSN: 0169409X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.addr.2008.10.002     Document Type: Review

References (84)

1. Jemal A., Siegel R., Ward E., Hao Y., Xu J., Murray T., and Thun M.J. Cancer statistics, 2008. CA. Cancer J. Clin. 58 2 (2008) 71-96
2. Pohl A., Zhang W., Ning Y., Manegold P.C., Lurje G., and Lenz H.J. Targeting metastatic colorectal cancer in 2008: a long way from 5-FU. Oncology (Willist. Park N. Y.) 22 4 (2008) 456-462
3. Lurje G., Pohl A., Manegold P.C., and Lenz H.J. Individualization of therapy based on clinical and molecular parameters. Curr. Colorectal Cancer Report 4 4 (2008) 193-200
4. Cunningham D., Humblet Y., Siena S., Khayat D., Bleiberg H., Santoro A., Bets D., Mueser M., Harstrick A., Verslype C., Chau I., and Van Cutsem E. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N. Engl. J. Med. 351 4 (2004) 337-345
5. Saltz L.B., Meropol N.J., Loehrer Sr P.J., Needle M.N., Kopit J., and Mayer R.J. Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor. J. Clin. Oncol. 22 7 (2004) 1201-1208
6. Compton C.C., and Greene F.L. The staging of colorectal cancer: 2004 and beyond, CA. Cancer J. Clin. 54 6 (2004) 295-308
7. Le Voyer T.E., Sigurdson E.R., Hanlon A.L., Mayer R.J., Macdonald J.S., Catalano P.J., and Haller D.G. Colon cancer survival is associated with increasing number of lymph nodes analyzed: a secondary survey of intergroup trial INT-0089. J. Clin. Oncol. 21 15 (2003) 2912-2919
8. Eschrich S., Yang I., Bloom G., Kwong K.Y., Boulware D., Cantor A., Coppola D., Kruhøffer M., Aaltonen L., Orntoft T.F., Quackenbush J., and Yeatman T.J. Molecular staging for survival prediction of colorectal cancer patients. J. Clin. Oncol. 23 15 (2005) 3526-3535
9. Dai Z., Papp A.C., Wang D., Hampel H., and Sadee W. Genotyping panel for assessing response to cancer chemotherapy. BMC Med. Genomics 1 (2008) 24
10. Benson III A.B., Schrag D., Somerfield M.R., Cohen A.M., Figueredo A.T., Flynn P.J., Krzyzanowska M.K., Maroun J., McAllister P., Van Cutsem E., Brouwers M., Charette M., and Haller D.G. American Society of Clinical Oncology recommendations on adjuvant chemotherapy for stage II colon cancer. J. Clin. Oncol. 22 16 (2004) 3408-3419
11. Popat S., Hubner R., and Houlston R.S. Systematic review of microsatellite instability and colorectal cancer prognosis. J. Clin. Oncol. 23 3 (2005) 609-618
12. Compton C.C., Fielding L.P., Burgart L.J., Conley B., Cooper H.S., Hamilton S.R., Hammond M.E., Henson D.E., Hutter R.V., Nagle R.B., Nielsen M.L., Sargent D.J., Taylor C.R., Welton M., and Willett C. Prognostic factors in colorectal cancer. College of American Pathologists Consensus Statement 1999. Arch. Pathol. Lab. Med. 124 7 (2000) 979-994
13. Locker G.Y., Hamilton S., Harris J., Jessup J.M., Kemeny N., Macdonald J.S., Somerfield M.R., Hayes D.F., Bast Jr. R.C., and ASCO. ASCO 2006 update of recommendations for the use of tumor markers in gastrointestinal cancer. J. Clin. Oncol. 24 33 (2006) 5313-5327
14. Watanabe T., Wu T.T., Catalano P.J., Ueki T., Satriano R., Haller D.G., Benson III A.B., and Hamilton S.R. Molecular predictors of survival after adjuvant chemotherapy for colon cancer. N. Engl. J. Med. 344 16 (2001) 1196-1206
15. Des Guetz G.U., Nicolas P., Schischmanoff P., and Morere J. Microsatellite instability as a predictor of chemotherapy efficacy in colorectal cancer. ASCO annual meeting. 2008. Chicago, IL, USA. J. Clin. Oncol. vol. 26 (2008) (May 20 suppl; abstr 4117)
16. Kakeji Y.O., Ohgaki K., Shibahara K., Shiotani S., Sadanaga N., Morita M., and Maehara Y. Microsatellite instability and oral fluoropyrimidine adjuvant chemotherapy in stage II and III colorectal cancer. ASCO annual meeting. 2008. Chicago, IL. J. Clin. Oncol. vol. 26 (2008) (May 20 suppl; abstr 15059)
17. Kim G.P., Colangelo L.H., Wieand H.S., Paik S., Kirsch I.R., Wolmark N., and Allegra C.J. National Cancer Institute, Prognostic and predictive roles of high-degree microsatellite instability in colon cancer: a National Cancer Institute-National Surgical Adjuvant Breast and Bowel Project Collaborative Study. J. Clin. Oncol. 25 7 (2007) 767-772
18. Sargent D.M., Thibodeau S.N., Labianca R., Hamilton S.R., Torri V., Monges G., Ribic C., Grothey A., and Gallinger S. Confirmation of deficient mismatch repair (dMMR) as a predictive marker for lack of benefit from 5-FU based chemotherapy in stage II and III colon cancer (CC): a pooled molecular reanalysis of randomized chemotherapy trials. ASCO annual meeting. Chicago, IL. J. Clin. Oncol. vol. 26 (2008) (May 20 suppl; abstr 4008)
19. Fearon E.R., Cho K.R., Nigro J.M., Kern S.E., Simons J.W., Ruppert J.M., Hamilton S.R., Preisinger A.C., Thomas G., and Kinzler K.W. Identification of a chromosome 18q gene that is altered in colorectal cancers. Science 247 4938 (1990) 49-56
20. Shibata D., Reale M.A., Lavin P., Silverman M., Fearon E.R., Steele Jr. G., Jessup J.M., Loda M., and Summerhayes I.C. The DCC protein and prognosis in colorectal cancer. N. Engl. J. Med. 335 23 (1996) 1727-1732
21. Oxaliplatin, leucovorin, and fluorouracil with or without bevacizumab in treating patients who have undergone surgery for stage ii colon cancer; Eastern Cooperative Oncology Group 5202. Available at: (July 19, 2007). http://clinicaltrials.gov/ct/show/NCT00217737 Accessed
22. Metzger R., Danenberg K., Leichman C.G., Salonga D., Schwartz E.L., Wadler S., Lenz H.J., Groshen S., Leichman L., and Danenberg P.V. High basal level gene expression of thymidine phosphorylase (platelet-derived endothelial cell growth factor) in colorectal tumors is associated with nonresponse to 5-fluorouracil. Clin. Cancer. Res. 4 10 (1998) 2371-2376
23. Johnston P.G., Lenz H.J., Leichman C.G., Danenberg K.D., Allegra C.J., Danenberg P.V., and Leichman L. Thymidylate synthase gene and protein expression correlate and are associated with response to 5-fluorouracil in human colorectal and gastric tumors. Cancer. Res. 55 7 (1995) 1407-1412
24. Milano G., Etienne M.C., Pierrefite V., Barberi-Heyob M., Deporte-Fety R., and Renée N. Dihydropyrimidine dehydrogenase deficiency and fluorouracil-related toxicity. Br. J. Cancer 79 3-4 (1999) 627-630
25. Soong R., Shah N., Salto-Tellez M., Tai B.C., Soo R.A., Han H.C., Ng S.S., Tan W.L., Zeps N., Joseph D., Diasio R.B., and Iacopetta B. Prognostic significance of thymidylate synthase, dihydropyrimidine dehydrogenase and thymidine phosphorylase protein expression in colorectal cancer patients treated with or without 5-fluorouracil-based chemotherapy. Ann. Oncol. 19 5 (2008) 915-919
26. Pullarkat S.T., Stoehlmacher J., Ghaderi V., Xiong Y.P., Ingles S.A., Sherrod A., Warren R., Tsao-Wei D., Groshen S., and Lenz H.J. Thymidylate synthase gene polymorphism determines response and toxicity of 5-FU chemotherapy. Pharmacogenomics J. 1 1 (2001) 65-70
27. Vallböhmer D., Iqbal S., Yang D.Y., Rhodes K.E., Zhang W., Gordon M., Fazzone W., Schultheis A.M., Sherrod A.E., Danenberg K.D., and Lenz H.J. Molecular determinants of irinotecan efficacy. Int. J. Cancer 119 10 (2006) 2435-2442
28. Camilleri M., and Saito Y.A. Pharmacogenomics in gastrointestinal disorders. Methods Mol. Biol. 448 (2008) 395-412
29. Lee A., Ezzeldin H., Fourie J., and Diasio R. Dihydropyrimidine dehydrogenase deficiency: impact of pharmacogenetics on 5-fluorouracil therapy. Clin. Adv. Hematol. Oncol. 2 8 (2004) 527-532
30. Mattison L.K., Soong R., and Diasio R.B. Implications of dihydropyrimidine dehydrogenase on 5-fluorouracil pharmacogenetics and pharmacogenomics. Pharmacogenomics 3 4 (2002) 485-492
31. Salonga D., Danenberg K.D., Johnson M., Metzger R., Groshen S., Tsao-Wei D.D., Lenz H.J., Leichman C.G., Leichman L., Diasio R.B., and Danenberg P.V. Colorectal tumors responding to 5-fluorouracil have low gene expression levels of dihydropyrimidine dehydrogenase, thymidylate synthase, and thymidine phosphorylase. Clin. Cancer Res. 6 4 (2000) 1322-1327
32. Vallböhmer D., Yang D.Y., Kuramochi H., Shimizu D., Danenberg K.D., Lindebjerg J., Nielsen J.N., Jakobsen A., and Danenberg P.V. DPD is a molecular determinant of capecitabine efficacy in colorectal cancer. Int. J. Oncol. 31 2 (2007) 413-418
33. Lurje G., Zhang W., Yang D., Groshen S., Hendifar A.E., Husain H., Nagashima F., Chang H.M., Fazzone W., Ladner R.D., Pohl A., Ning Y., Iqbal S., El-Khoueiry A., and Lenz H.J. Thymidylate synthase haplotype is associated with tumor recurrence in stage II and stage III colon cancer. Pharmacogenetics Genomics 18 2 (2008) 161-168
34. Leichman C.G., Lenz H.J., Leichman L., Danenberg K., Baranda J., Groshen S., Boswell W., Metzger R., Tan M., and Danenberg P.V. Quantitation of intratumoral thymidylate synthase expression predicts for disseminated colorectal cancer response and resistance to protracted-infusion fluorouracil and weekly leucovorin. J. Clin. Oncol. 15 10 (1997) 3223-3229
35. Gorlick R., Metzger R., Danenberg K.D., Salonga D., Miles J.S., Longo G.S., Fu J., Banerjee D., Klimstra D., Jhanwar S., Danenberg P.V., Kemeny N., and Bertino J.R. Higher levels of thymidylate synthase gene expression are observed in pulmonary as compared with hepatic metastases of colorectal adenocarcinoma. J. Clin. Oncol. 16 4 (1998) 1465-1469
36. Villafranca E., Okruzhnov Y., Dominguez M.A., García-Foncillas J., Azinovic I., Martínez E., Illarramendi J.J., Arias F., Martínez Monge R., Salgado E., Angeletti S., and Brugarolas A. Polymorphisms of the repeated sequences in the enhancer region of the thymidylate synthase gene promoter may predict downstaging after preoperative chemoradiation in rectal cancer. J. Clin. Oncol. 19 6 (2001) 1779-1786
37. Funke S., Brenner H., and Chang-Claude J. Pharmacogenetics in colorectal cancer: a systematic review. Pharmacogenomics 9 8 (2008) 1079-1099
38. Kwon H.C., Roh M.S., Oh S.Y., Kim S.H., Kim M.C., Kim J.S., and Kim H.J. Prognostic value of expression of ERCC1, thymidylate synthase, and glutathione S-transferase P1 for 5-fluorouracil/oxaliplatin chemotherapy in advanced gastric cancer. Ann. Oncol. 18 3 (2007) 504-509
39. Di Francesco A.M., Ruggiero A., and Riccardi R. Cellular and molecular aspects of drugs of the future: oxaliplatin. Cell. Mol. Life Sci. 59 11 (2002) 1914-1927
40. Kweekel D.M., Gelderblom H., and Guchelaar H.J. Pharmacology of oxaliplatin and the use of pharmacogenomics to individualize therapy. Cancer Treat. Rev. 31 2 (2005) 90-105
41. Lévi F., Metzger G., Massari C., and Milano G. Oxaliplatin: pharmacokinetics and chronopharmacological aspects. Clin. Pharmacokinet. 38 1 (2000) 1-21
42. Johnson N.P., Hoeschele J.D., and Rahn R.O. Kinetic analysis of the in vitro binding of radioactive cis- and trans-dichlorodiammineplatinum(II) to DNA. Chem. Biol. Interact. 30 2 (1980) 151-169
43. Martin L.P., Hamilton T.C., and Schilder R.J. Platinum resistance: the role of DNA repair pathways. Clin. Cancer Res. 14 5 (2008) 1291-1295
44. Shirota Y., Stoehlmacher J., Brabender J., Xiong Y.P., Uetake H., Danenberg K.D., Groshen S., Tsao-Wei D.D., Danenberg P.V., and Lenz H.J. ERCC1 and thymidylate synthase mRNA levels predict survival for colorectal cancer patients receiving combination oxaliplatin and fluorouracil chemotherapy. J. Clin. Oncol. 19 23 (2001) 4298-4304
45. Lenz H.J., Zhan W., Shi M.M., Jacques C., Barrett J.C., Danenberg K.D., Hoffmann A.C., Trarbach T., Folprecht G., Meinhardt G., and Yang D. ERCC-1 gene expression levels and outcome to FOLFOX chemotherapy in patients enrolled in CONFIRM1 and CONFIRM2. ASCO annual meeting. 2008, Chicago, IL, USA. J. Clin. Oncol. vol. 26 (2008) (May 20 suppl; abstr 4131)
46. Metzger R., Leichman C.G., Danenberg K.D., Danenberg P.V., Lenz H.J., Hayashi K., Groshen S., Salonga D., Cohen H., Laine L., Crookes P., Silberman H., Baranda J., Konda B., and Leichman L. ERCC1 mRNA levels complement thymidylate synthase mRNA levels in predicting response and survival for gastric cancer patients receiving combination cisplatin and fluorouracil chemotherapy. J. Clin. Oncol. 16 1 (1998) 309-316
47. Stoehlmacher J., Park D.J., Zhang W., Yang D., Groshen S., Zahedy S., and Lenz H.J. A multivariate analysis of genomic polymorphisms: prediction of clinical outcome to 5-FU/oxaliplatin combination chemotherapy in refractory colorectal cancer. Br. J. Cancer 91 2 (2004) 344-354
48. Ruzzo A., Graziano F., Loupakis F., Rulli E., Canestrari E., Santini D., Catalano V., Ficarelli R., Maltese P., Bisonni R., Masi G., Schiavon G., Giordani P., Giustini L., Falcone A., Tonini G., Silva R., Mattioli R., Floriani I., and Magnani M. Pharmacogenetic profiling in patients with advanced colorectal cancer treated with first-line FOLFOX-4 chemotherapy. J. Clin. Oncol. 25 10 (2007) 1247-1254
49. Viguier J., Boige V., Miquel C., Pocard M., Giraudeau B., Sabourin J.C., Ducreux M., Sarasin A., and Praz F. ERCC1 codon 118 polymorphism is a predictive factor for the tumor response to oxaliplatin/5-fluorouracil combination chemotherapy in patients with advanced colorectal cancer. Clin. Cancer. Res. 11 17 (2005) 6212-6217
50. de Jong F.A., de Jonge M.J., Verweij J., and Mathijssen R.H. Role of pharmacogenetics in irinotecan therapy. Cancer Lett. 234 1 (2006) 90-106
51. Slatter J.G., Schaaf L.J., Sams J.P., Feenstra K.L., Johnson M.G., Bombardt P.A., Cathcart K.S., Verburg M.T., Pearson L.K., Compton L.D., Miller L.L., Baker D.S., Pesheck C.V., and Lord III R.S. Pharmacokinetics, metabolism, and excretion of irinotecan (CPT-11) following I.V. infusion of [(14)C]CPT-11 in cancer patients. Drug Metab. Dispos. 28 4 (2000) 423-433
52. Bosma P.J., Chowdhury J.R., Bakker C., Gantla S., de Boer A., Oostra B.A., Lindhout D., Tytgat G.N.J., Jansen P.L.M., Oude Elferink R.P.J., and Chowdhury N.R. The genetic basis of the reduced expression of bilirubin UDP-glucuronosyltransferase 1 in Gilbert's syndrome. N. Engl. J. Med. 333 18 (1995) 1171-1175
53. Monaghan G., Ryan M., Seddon R., Hume R., and Burchell B. Genetic variation in bilirubin UPD-glucuronosyltransferase gene promoter and Gilbert's syndrome. Lancet, 347 9001 (1996) 578-581
54. Gelbart E., and Demina A. Racial variability in the UDP-glucuronosyltransferase 1 (UGT1A1) promoter: a balanced polymorphism for regulation of bilirubin metabolism?. Proc. Natl. Acad. Sci. U.S.A. 95 14 (1998) 8170-8174
55. Desai A.A., Innocenti F., and Ratain M.J. Pharmacogenomics: road to anticancer therapeutics nirvana?. Oncogene 22 42 (2003) 6621-6628
56. Romero R.Z., Morales R., Garcia F., Huarriz M., Bandres E., De la Haba J., Gómez A., Aranda E., and García-Foncillas J. Potential application of GSTT1-null genotype in predicting toxicity associated to 5-fluouracil irinotecan and leucovorin regimen in advanced stage colorectal cancer patients. Oncol. Rep. 16 3 (2006) 497-503
57. Rouits E., Boisdron-Celle M., Dumont A., Guérin O., Morel A., and Gamelin E. Relevance of different UGT1A1 polymorphisms in irinotecan-induced toxicity: a molecular and clinical study of 75 patients. Clin. Cancer Res. 10 15 (2004) 5151-5159
58. Toffoli G., Cecchin E., Corona G., Russo A., Buonadonna A., D'Andrea M., Pasetto L.M., Pessa S., Errante D., De Pangher V., Giusto M., Medici M., Gaion F., Sandri P., Galligioni E., Bonura S., Boccalon M., Biason P., and Frustaci S. The role of UGT1A1*28 polymorphism in the pharmacodynamics and pharmacokinetics of irinotecan in patients with metastatic colorectal cancer. J. Clin. Oncol. 24 19 (2006) 3061-3068
59. Innocenti F., Undevia S.D., Iyer L., Chen P.X., Das S., Kocherginsky M., Karrison T., Janisch L., Ramírez J., Rudin C.M., Vokes E.E., and Ratain M.J. Genetic variants in the UDP-glucuronosyltransferase 1A1 gene predict the risk of severe neutropenia of irinotecan. J. Clin. Oncol. 22 8 (2004) 1382-1388
60. Messa C., Russo F., Caruso M.G., and Di Leo A. EGF, TGF-alpha, and EGF-R in human colorectal adenocarcinoma. Acta. Oncol. 37 3 (1998) 285-289
61. Porebska I., Harlozinska A., and Bojarowski T. Expression of the tyrosine kinase activity growth factor receptors (EGFR, ERB B2, ERB B3) in colorectal adenocarcinomas and adenomas. Tumour Biol. 21 2 (2000) 105-115
62. Salomon D.S., Brandt R., Ciardiello F., and Normanno N. Epidermal growth factor-related peptides and their receptors in human malignancies. Crit. Rev. Oncol./Hematol. 19 3 (1995) 183-232
63. Syed S., and Rowinsky E. The new generation of targeted therapies for breast cancer. Oncology (Willist. Park N. Y.) 17 10 (2003) 1339-1351
64. Adjei A.A., and Rowinsky E.K. Novel anticancer agents in clinical development. Cancer Biol. Ther. 2 4 Suppl 1 (2003) S5-S15
65. Amado R.G., Wolf M., Peeters M., Van Cutsem E., Siena S., Freeman D.J., Juan T., Sikorski R., Suggs S., Radinsky R., Patterson S.D., and Chang D.D. Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. J. Clin. Oncol. 26 10 (2008) 1626-1634
66. Van Cutsem E., Peeters M., Siena S., Humblet Y., Hendlisz A., Neyns B., Canon J.L., Van Laethem J.L., Maurel J., Richardson G., Wolf M., and Amado R.G. Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer. J. Clin. Oncol. 25 13 (2007) 1658-1664
67. Chung K.Y., Shia J., Kemeny N.E., Shah M., Schwartz G.K., Tse A., Hamilton A., Pan D., Schrag D., Schwartz L., Klimstra D.S., Fridman D., Kelsen D.P., and Saltz L.B. Cetuximab shows activity in colorectal cancer patients with tumors that do not express the epidermal growth factor receptor by immunohistochemistry. J. Clin. Oncol. 23 9 (2005) 1803-1810
68. Hebbar M., Wacrenier A., Desauw C., Romano O., Cattan S., Triboulet JP., and Pruvot F.R. Lack of usefulness of epidermal growth factor receptor expression determination for cetuximab therapy in patients with colorectal cancer. Anticancer Drugs 17 7 (2006) 855-857
69. Press M.F., and Lenz H.J. EGFR, HER2 and VEGF pathways: validated targets for cancer treatment. Drugs 67 14 (2007) 2045-2075
70. Saltz L., Kies M., Abbruzzese J.L., Azaria N., and Needle M. The presence and intensity of the cetuximab-induced acne-like rash predicts increased survival in studies across multiple malignancies. in ASCO annual meeting. 2003. Proc. Am. Soc. Clin. Oncol. 22 (2003) (abstr 817)
71. Tejpar S., Peters M., Humblet Y., Gelderblom H., Vermorken J., Viret F., Glimelius B., Ciardiello F., Kisker O., and Van Cutsem E. Phase I/II study of cetuximab dose-escalation in patients with metastatic colorectal cancer (mCRC) with no or slight skin reactions on cetuximab standard dose treatment (EVEREST): Pharmacokinetic (PK), Pharmacodynamic (PD) and efficacy data. ASCO. 2007. Chicago, Illinois. J. Clin. Oncol. 2007 ASCO Annual Meeting Proceedings Part I vol. 25 (18S) (2007) 4037
72. De Roock W., Piessevaux H., De Schutter J., Janssens M., De Hertogh G., Personeni N., Biesmans B., Van Laethem J.L., Peeters M., Humblet Y., Van Cutsem E., and Tejpar S. KRAS wild-type state predicts survival and is associated to early radiological response in metastatic colorectal cancer treated with cetuximab. Ann. Oncol. 19 3 (2008) 508-515
73. Khambata-Ford S., Garrett C.R., Meropol N.J., Basik M., Harbison C.T., Wu S., Wong T.W., Huang X., Takimoto C.H., Godwin A.K., Tan B.R., Krishnamurthi S.S., Burris III H.A., Poplin E.A., Hidalgo M., Baselga J., Clark E.A., and Mauro D.J. Expression of epiregulin and amphiregulin and K-ras mutation status predict disease control in metastatic colorectal cancer patients treated with cetuximab. J. Clin. Oncol. 25 22 (2007) 3230-3237
74. Lièvre A., Bachet J.B., Boige V., Cayre A., Le Corre D., Buc E., Ychou M., Bouché O., Landi B., Louvet C., André T., Bibeau F., Diebold M.D., Rougier P., Ducreux M., Tomasic G., Emile J.F., Penault-Llorca F., and Laurent-Puig P. KRAS mutations as an independent prognostic factor in patients with advanced colorectal cancer treated with cetuximab. J. Clin. Oncol. 26 3 (2008) 374-379
75. Van Cutsem E., Lang I., D'haens G., Moiseyenko V., Zaluski J., Folprecht G., Tejpar S., Kisker O., Stroh C., and Rougier P. KRAS status and efficacy in the first-line treatment of patients with metastatic colorectal cancer (mCRC) treated with FOLFIRI with or without cetuximab: the CRYSTAL experience. ASCO annual meeting. 2008. Chicago, IL, USA. J. Clin. Oncol. vol. 26 (2008) (May 20 suppl; abstr 2)
76. Bokemeyer C., Bondarenko I., Hartmann J.T., De Brand F.G., Volovat C., Nippgen J., Stroh C., Celik I., and Koralewski P. KRAS status and efficacy of first-line treatment of patients with metastatic colorectal cancer (mCRC) with FOLFOX with or without cetuximab: the OPUS experience. ASCO annual meeting. 2008. Chicago, IL, USA. J. Clin. Oncol. vol. 26 (2008) (May 20 suppl; abstr 4000)
77. Cappuzzo F., Finocchiaro G., Rossi E., Jänne P.A., Carnaghi C., Calandri C., Bencardino K., Ligorio C., Ciardiello F., Pressiani T., Destro A., Roncalli M., Crino L., Franklin W.A., Santoro A., and Varella-Garcia M. EGFR FISH assay predicts for response to cetuximab in chemotherapy refractory colorectal cancer patients. Ann. Oncol. 19 4 (2008) 717-723
78. Moroni M., Veronese S., Benvenuti S., Marrapese G., Sartore-Bianchi A., Di Nicolantonio F., Gambacorta M., Siena S., and Bardelli A. Gene copy number for epidermal growth factor receptor (EGFR) and clinical response to antiEGFR treatment in colorectal cancer: a cohort study. Lancet Oncol. 6 5 (2005) 279-286
79. Sartore-Bianchi A., Moroni M., Veronese S., Carnaghi C., Bajetta E., Luppi G., Sobrero A., Barone C., Cascinu S., Colucci G., Cortesi E., Nichelatti M., Gambacorta M., and Siena S. Epidermal growth factor receptor gene copy number and clinical outcome of metastatic colorectal cancer treated with panitumumab. J. Clin. Oncol. 25 22 (2007) 3238-3245
80. Personeni N., Fieuws S., Piessevaux H., De Hertogh G., De Schutter J., Biesmans B., De Roock W., Capoen A., Debiec-Rychter M., Van Laethem J.L., Peeters M., Humblet Y., Van Cutsem E., and Tejpar S. Clinical usefulness of EGFR gene copy number as a predictive marker in colorectal cancer patients treated with cetuximab: a fluorescent in situ hybridization study. Clin. Cancer Res. 14 18 (2008) 5869-5876
81. Lurje G., Nagashima F., Zhang W., Yang D., Chang H.M., Gordon M.A., El-Khoueiry A., Husain H., Wilson P.M., Ladner R.D., Mauro D.J., Langer C., Rowinsky E.K., and Lenz H.J. Polymorphisms in cyclooxygenase-2 and epidermal growth factor receptor are associated with progression-free survival independent of K-ras in metastatic colorectal cancer patients treated with single-agent cetuximab. Clin. Cancer Res. 14 23 (2008) 7884-7895
82. Hurwitz H., Fehrenbacher L., Novotny W., Cartwright T., Hainsworth J., Heim W., Berlin J., Baron A., Griffing S., Holmgren E., Ferrara N., Fyfe G., Rogers B., Ross R., and Kabbinavar F. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N. Engl. J. Med. 350 23 (2004) 2335-2342
83. A.M. Schultheis, G. Lurje, K.E. Rhodes, W. Zhang, D. Yang, A.A. Garcia, R. Morgan, D. Gandara, S. Scudder, A. Oza, H. Hirte, G. Fleming, L. Roman, H.J. Lenz, Polymorphisms and clinical outcome in recurrent ovarian cancer treated with cyclophosphamide and bevacizumab. Clin. Cancer Res. 14 (22) (2008) 7554-7563.
84. Ince W.L., Jubb A.M., Holden S.N., Holmgren E.B., Tobin P., Sridhar M., Hurwitz H.I., Kabbinavar F., Novotny W.F., Hillan K.J., and Koeppen H. Association of K-ras, b-raf, and p53 status with the treatment effect of bevacizumab. J. Natl. Cancer Inst. 97 13 (2005) 81-89